Boston Scientific Corpora... (BSX)
104.80
1.01 (0.97%)
At close: Mar 03, 2025, 3:59 PM
104.87
0.07%
After-hours: Mar 03, 2025, 07:00 PM EST
Boston Scientific Corporation Revenue Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardiovascular Revenue | 2.73B | 2.64B | 2.44B | 2.29B | 2.19B | 2.24B | 2.11B | 2.13B | 2.06B | 2.07B | 1.9B | 1.27B | 1.2B | 1.26B | 1.13B | 1.01B | 1B | 834M | 1.03B | 1.2B | 1.01B | 1.03B | 972M | 971M | 908M | 965M | 933M | 883M | 857M | 889M | 871M | 0 | 2.69B | 1.79B | 877M | 835M | 797M | 812M | 773M | 779M | 731M | 738M | 705M | 728M | 689M | 742M | 708M |
Cardiovascular Revenue Growth | +3.56% | +7.85% | +7.00% | +4.58% | -2.41% | +6.11% | -0.85% | +3.05% | -0.05% | +8.62% | +49.76% | +6.19% | -5.30% | +11.87% | +11.34% | +1.20% | +20.14% | -18.71% | -14.43% | +18.60% | -1.46% | +5.56% | +0.10% | +6.94% | -5.91% | +3.43% | +5.66% | +3.03% | -3.60% | +2.07% | n/a | -100.00% | +50.00% | +104.10% | +5.03% | +4.77% | -1.85% | +5.05% | -0.77% | +6.57% | -0.95% | +4.68% | -3.16% | +5.66% | -7.14% | +4.80% | n/a |
MedSurg Revenue | 1.48B | 1.48B | 1.41B | 1.44B | 1.34B | 1.36B | 1.28B | 1.35B | 1.26B | 1.28B | 1.16B | 999M | 917M | 948M | 860M | 891M | 825M | 576M | 774M | 878M | 845M | 818M | 766M | 799M | 746M | 751M | 711M | 915M | 827M | 841M | 794M | 0 | 2.33B | 1.53B | 733M | 779M | 697M | 619M | 574M | 634M | 593M | 581M | 551M | 625M | 581M | 571M | 521M |
MedSurg Revenue Growth | -0.27% | +5.03% | -2.01% | +7.46% | -1.40% | +6.25% | -5.54% | +7.54% | -1.41% | +9.79% | +16.52% | +8.94% | -3.27% | +10.23% | -3.48% | +8.00% | +43.23% | -25.58% | -11.85% | +3.91% | +3.30% | +6.79% | -4.13% | +7.10% | -0.67% | +5.63% | -22.30% | +10.64% | -1.66% | +5.92% | n/a | -100.00% | +51.96% | +109.00% | -5.91% | +11.76% | +12.60% | +7.84% | -9.46% | +6.91% | +2.07% | +5.44% | -11.84% | +7.57% | +1.75% | +9.60% | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|---|---|---|---|---|
Non-Us Revenue | 5.82B | 2.12B | 4.98B | 4.21B | 1.9B | 1.73B | 3.76B | 4.01B | 1.88B |
Non-Us Revenue Growth | +174.86% | -57.49% | +18.19% | +121.92% | +9.90% | -54.02% | -6.33% | +113.41% | n/a |
United States Revenue | 8.43B | 2.53B | 1.51B | 1B | 2.26B | 2.18B | n/a | n/a | n/a |
United States Revenue Growth | +233.53% | +67.51% | +50.80% | -55.83% | +4.04% | n/a | n/a | n/a | n/a |
Asia Pacific Revenue | 2.4B | 469M | n/a | n/a | 395M | 383M | n/a | n/a | n/a |
Asia Pacific Revenue Growth | +411.73% | n/a | n/a | n/a | +3.13% | n/a | n/a | n/a | n/a |
Emea Revenue | 2.86B | 5.11B | n/a | n/a | 4.57B | 4.29B | n/a | n/a | n/a |
Emea Revenue Growth | -44.12% | n/a | n/a | n/a | +6.60% | n/a | n/a | n/a | n/a |
Latin America And Canada Revenue | 560M | 3.27B | n/a | n/a | 1.29B | 5.54B | n/a | n/a | n/a |
Latin America And Canada Revenue Growth | -82.88% | n/a | n/a | n/a | -76.65% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
Quarter | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 1.61B | 1.56B | 1.45B | 1.36B | 1.38B | 1.24B | 1.35B | 1.22B | 1.16B | 1.13B | 1.17B | 1.06B | 1.15B | 1.07B | 1.12B | 1.02B | 1.03B | 984M | 798M | 978M | 1.09B | 1.01B | 968M | 869M | 953M | 870M | 886M | 860M | 886M | 800M | 815M | 794M | 831M | 772M | 779M | 716M | 777M | 729M | 700M | 668M |
Selling, General, and Administrative Revenue Growth | +3.20% | +8.02% | +6.01% | -1.09% | +11.03% | -8.27% | +11.44% | +4.47% | +2.74% | -2.83% | +9.91% | -8.07% | +8.16% | -4.91% | +10.01% | -0.78% | +4.37% | +23.31% | -18.40% | -10.44% | +7.91% | +4.55% | +11.39% | -8.81% | +9.54% | -1.81% | +3.02% | -2.93% | +10.75% | -1.84% | +2.64% | -4.45% | +7.64% | -0.90% | +8.80% | -7.85% | +6.58% | +4.14% | +4.79% | n/a |
Research and Development Revenue | 459M | 407M | 383M | 366M | 363M | 356M | 359M | 337M | 330M | 339M | 335M | 319M | 320M | 310M | 298M | 276M | 286M | 315M | 242M | 300M | 309M | 306M | 280M | 280M | 288M | 289M | 275M | 261M | 264M | 254M | 244M | 235M | 256M | 232M | 222M | 210M | 244M | 221M | 220M | 192M |
Research and Development Revenue Growth | +12.78% | +6.27% | +4.64% | +0.83% | +1.97% | -0.84% | +6.53% | +2.12% | -2.65% | +1.19% | +5.02% | -0.31% | +3.23% | +4.03% | +7.97% | -3.50% | -9.21% | +30.17% | -19.33% | -2.91% | +0.98% | +9.29% | n/a | -2.78% | -0.35% | +5.09% | +5.36% | -1.14% | +3.94% | +4.10% | +3.83% | -8.20% | +10.34% | +4.50% | +5.71% | -13.93% | +10.41% | +0.45% | +14.58% | n/a |